INS and type 1 diabetes mellitus: In a phase III RCT of sotagliflozin administered in combination with insulin to 1,402 adults with T1D, 24 weeks of treatment with sotagliflozin decreased the HbA1c level by 0.46%, body weight by 2.98 kg, and insulin dose by 2.8 U/day (1).